Status: Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Participants needed: 91
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Alexion Pharmaceuticals, Inc.Updated: Jul 2, 2026Locations: 18
Eligibility criteria
Confirmed histopathological diagnosis of AL amyloidosis [+6]
Have any other form of amyloidosis other than AL amyloidosis [+11]